Lysosomal Therapeutics Lands $20,000,000 Series A Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=88656b3c-e6c1-4ee4-a3e1-d4b4a01ebc98
Date
2/3/2015
Company Name
Lysosomal Therapeutics
Mailing Address
19 Blackstone Street Cambridge, MA 02139 USA
Company Description
LTI’s unique approach to discovering new drugs for neurodegenerative diseases is based on research performed in the lab of Dr. Dimitri Krainc, one of the company’s founders, at Massachusetts General Hospital (MGH), a founding member of Partners HealthCare and an affiliate of Harvard Medical School.
Website
http://www.lysosomaltx.com
Transaction Type
Venture Equity
Transaction Amount
$20,000,000
Transaction Round
Series A
Proceeds Purposes
The proceeds will fund ongoing compound optimization and preclinical development of a glucocerebrosidase (GCase) lysosomal enzyme activator candidate for the treatment of Parkinson’s disease. In addition, the funding will support a biomarker initiative, for which LTI has previously received grant funding from The Michael J. Fox Foundation for Parkinson’s Research.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor